{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:29:44Z","timestamp":1762144184010},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":4724,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2000,4]]},"abstract":"<jats:p>Motion sickness and the antimotion sickness drugs scopolamine (SCP) and promethazine (PMZ) inhibit gastric emptying (GE). This study was conducted to determine if erythromycin would exert its well\u2010known prokinetic effects in normal and motion\u2010sick subjects given antimotion sickness drugs. Fifteen fasted volunteers (11 males, 4 females) participated in the study In control tests, 8 subjects were given intramuscular (IM) saline (SAL, 0.5 ml), SCP (0.1 mg), or PMZ (25 mg). GE of liquid (300 ml) containing 1 mCi of Tc 99m diethylenetria\u2010minepentaacetic acid (DTPA) was measured by sequential gastric scintigraphy 30 minutes after IM treatments. In other tests, GE was measured in 8 subjects after each IM treatment, followed 10 minutes later by 200 mg of erythromycin thylsuccinate (ESS) suspension given orally. In a third group of tests, 7 subjects received an IM treatment, oral EES 10 minutes later, and were then brought to an advanced level of motion sickness short of vomiting. To induce motion sickness, blindfolded subjects made timed head movements while seated in a rotating chair. GE was measured immediately after rotation. GE half\u2010life, rate constant, area under the curve (AUC), and lag time were calculated using conventional mathematical methods for analyzing exponential rate processes. GE parameters calculated for normal and motion\u2010sick subjects given antimotion sickness drugs and EES were compared with those from subjects given IM treatments (control) only. In normal subjects, EES significantly (p &lt; 0.05) increased the GE rate constant for all IM treatments and reduced the AUC for SAL, SCP, and PMZ by 49% (p &lt; 0.05), 44% (p &lt; 0.05), and 69% (p &lt; 0.01), respectively. In motion\u2010sick subjects, lag time was significantly (p &lt; 0.05) increased, and the rate constant and AUC values were unchanged from control for all IM treatments. The authors conclude that oral EES reverses the gastrostatic actions of the antimotion sickness drugs but does not affect the inhibition of gastric emptying associated with motion sickness. The results suggest that motion sickness and antimotion sickness drugs reduce GE through different mechanisms.<\/jats:p>","DOI":"10.1177\/00912700022009044","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"347-353","source":"Crossref","is-referenced-by-count":13,"title":["Prokinetic Effects of Erythromycin after Antimotion Sickness Drugs"],"prefix":"10.1002","volume":"40","author":[{"given":"John J.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy C.","family":"Parish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles D.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1112","article-title":"Nuclear medicine evaluation of motion sickness and medications on gastric emptying time","volume":"58","author":"Wood MJ","year":"1987","journal-title":"Aviat Space Environ Med."},{"issue":"2","key":"e_1_2_1_3_2","first-page":"103","article-title":"Gastric emptying and the symptoms of vection\u2010induced nausea","volume":"7","author":"Reid K","year":"1995","journal-title":"Europ J Gastroenterol & Hepat."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb02017.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb03803.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02093798"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00177.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.148324000.x"},{"key":"e_1_2_1_9_2","first-page":"2011","article-title":"Erythromycin as a prokinetic agent: a prospective, randomized, controlled study of efficacy in nasoenteric tube placement","volume":"89","author":"Stern MA","year":"1994","journal-title":"Amer J Gastroenterol."},{"key":"e_1_2_1_10_2","first-page":"453","article-title":"Diagnostic criteria for grading the severity of acute motion sickness","volume":"39","author":"Graybiel A","year":"1968","journal-title":"Aerospace Med."},{"key":"e_1_2_1_11_2","volume-title":"Manual of Pharmacologic Calculation with Computer Programs","author":"Tallarida RJ","year":"1987"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00606.x"},{"key":"e_1_2_1_13_2","first-page":"63","article-title":"Differentiation of muscarinic cholingeric receptor subtypes in human cortex and pons: implications for anti\u2010motion sickness therapy","volume":"59","author":"McCarthy BG","year":"1988","journal-title":"Aviat Space & Environ Med."},{"key":"e_1_2_1_14_2","volume-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"Babe KS","year":"1996"},{"key":"e_1_2_1_15_2","first-page":"1074","article-title":"Tachygastria and motion sickness","volume":"56","author":"Stern RM","year":"1985","journal-title":"Aviat Space Environ Med."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02093824"},{"key":"e_1_2_1_17_2","first-page":"821","article-title":"Hormonal changes after parabolic flight: implications on the development of motion sickness","volume":"61","author":"Drummer C","year":"1990","journal-title":"Aviat Space Environ Med."},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8986.1986.tb00671.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb02016.x"},{"key":"e_1_2_1_20_2","first-page":"G853","article-title":"Role of plasma vasopressin as a mediator of nausea and gastric slow wave dysrhythmias in motion sickness","volume":"35","author":"Kim MS","year":"1997","journal-title":"Am J Physiol."},{"key":"e_1_2_1_21_2","first-page":"G539","article-title":"Central cholinergic and alpha\u2010adrenergic mediation of gastric slow wave dysrhythmias evoked during motion sickness","volume":"268","author":"Hasler WL","year":"1995","journal-title":"Amer J Physiol."},{"key":"e_1_2_1_22_2","first-page":"485","article-title":"Erythromycin: a motilin agonist and gastrointestinal prokinetic agent","volume":"88","author":"Weber FH","year":"1993","journal-title":"Amer J Gastroenterol."},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90387-S"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.148324000.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01536806"},{"key":"e_1_2_1_26_2","first-page":"G50","article-title":"Erythromycin contracts rabbit colon myocytes via occupation of motilin receptors","volume":"262","author":"Hasler WL","year":"1992","journal-title":"Am J Physiol."},{"key":"e_1_2_1_27_2","first-page":"G418","article-title":"Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach","volume":"269","author":"Parkman HP","year":"1995","journal-title":"Am J Physiol."},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8780573"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90383-V"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1998.tb00957.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912700022009044","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912700022009044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T11:45:51Z","timestamp":1698579951000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912700022009044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["10.1177\/00912700022009044"],"URL":"https:\/\/doi.org\/10.1177\/00912700022009044","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}